7 Best Peptides for Panic Attacks

What to Know Before Choosing a Peptide for Panic Attacks

Panic attacks sit at the intersection of some of the most active areas in neuropeptide research. Brain pathways involving peptides like Atrial Natriuretic Peptide, Neuropeptide Y, and PACAP are now known to play direct roles in triggering and suppressing panic responses. That has generated real scientific interest in whether some of these compounds, or synthetic analogs that work on related pathways, might offer something beyond what SSRIs and benzodiazepines currently provide.

Every compound in this guide earned a slot because people use it, or are actively discussing using it, for panic attacks. That is the only test applied here. FDA approval status, telemedicine prescription access, and research-only classification are all treated equally. A compound approved only in Russia belongs if people are seeking it for this goal. A compound with only community-reported use belongs if that use is real and consistent. What changes between entries is not whether a compound appears but how honestly its evidence is described.

The order reflects how prominently each compound appears in research and in real-world use for panic attacks, not a ranking of one compound being better than another for you. Some entries here have small human trials behind them. Others rest almost entirely on animal data or user reports. The right choice for any individual depends on factors the app, not this article, is built to sort through.

One important note before the entries: BPC-157 comes up in community discussions of panic attacks, but for a troubling reason. Multiple users have reported that BPC-157 triggered severe panic episodes. That compound is not included as a treatment option here, and people with a history of panic disorder should be aware of that pattern before making any decisions.

1. Selank: The Most Studied Option for Anxiety and Panic

Selank is a synthetic heptapeptide, a short chain of seven amino acids, originally developed in Russia as an analog of tuftsin, a naturally occurring peptide involved in immune regulation. In Russian clinical psychiatry it is an approved drug for anxiety and depression, and it is the compound that comes up most consistently when people in community forums discuss peptides for panic disorder specifically.

The mechanism behind Selank is what makes it stand out for this goal. It modulates GABA-A receptors, the same receptor family that benzodiazepines act on, but appears to do so through a different route, one that produces anxiolytic effects without the sedation or dependence risk associated with drugs like diazepam. It also influences serotonin and dopamine signaling and appears to slow the breakdown of enkephalins, naturally occurring compounds involved in pain and anxiety regulation. Together these effects give it a more mechanistically grounded profile than most compounds discussed for panic.

Clinical studies conducted in Russia, cited in the published literature under Filatova and colleagues from 2017, found that Selank produced anxiolytic effects comparable to diazepam on measured outcomes while preserving focus and avoiding sedation. Animal research in rodent models confirmed the anxiety-reducing effects and supported the lower-sedation profile. No large-scale randomized controlled trial has been conducted specifically in panic disorder patients, and the available human data comes from general anxiety populations rather than people whose primary diagnosis is panic disorder.

Real-world user reports are the most direct evidence for panic-specific use, and they are strikingly consistent for a research-chemical compound. Across multiple threads on communities focused on panic attacks, users report meaningful reductions in both baseline anxiety and the frequency of panic episodes. Some describe the effect as anxiety becoming manageable rather than absent; a smaller number report more complete resolution of panicky thinking within days of starting use. Users consistently describe it as non-sedating and non-habit-forming, which matters considerably for people wary of benzodiazepine dependence. Nasal spray is the most commonly reported delivery route, though subcutaneous injection is also used.

In the United States, Selank occupies a regulatory gray zone. It is not FDA-approved for any indication, and compounding pharmacy access has become more restricted since 2023 policy changes affecting several peptides. Purity varies between sources because there are no standardized manufacturing requirements for research-chemical vendors. Anyone considering Selank needs to understand that obtaining it means operating outside the standard pharmaceutical supply chain.

2. Semax: For Mood Stability and Stress-Circuit Support

Semax is a synthetic peptide derived from a fragment of ACTH, adrenocorticotropic hormone, the pituitary hormone that drives cortisol release during stress. Like Selank, it is an approved drug in Russia, where it is used for stroke recovery and depression, and it reaches people in the United States through the same compounding and research-chemical channels.

Its relevance to panic attacks is less direct than Selank's but still grounded in biology. Semax increases BDNF, brain-derived neurotrophic factor, a protein that supports neuron survival and growth and is closely tied to resilience against anxiety and depression. It also appears to influence connectivity between the prefrontal cortex and the amygdala, the circuit that governs how the brain regulates fear responses. When that circuit is dysregulated, fear signals from the amygdala are less effectively modulated by the prefrontal cortex, a pattern consistently observed in panic disorder. By supporting neuroplasticity along this circuit, Semax may help rebuild the brain's capacity to keep fear responses in proportion.

No human clinical trial data specific to panic disorder has been published for Semax. The evidence for its mood and anxiety effects comes from Russian clinical research on depression and from mechanistic studies on the BDNF pathway, neither of which maps directly onto panic attacks. Community use is real: Semax appears frequently alongside Selank in anxiety and panic protocols, often described as complementary, with Semax handling mood stability and cognitive clarity while Selank addresses the more acute anxiety component.

One specific safety flag from the regulatory record deserves mention. The FDA has flagged potential immunogenicity risks for compounded Semax, meaning allergic or immune reactions depending on route of administration. That finding distinguishes Semax from Selank in the safety picture and warrants direct discussion with a knowledgeable clinician before pursuing it.

3. Atrial Natriuretic Peptide: The Strongest Panic-Specific Clinical Evidence

Atrial Natriuretic Peptide, abbreviated ANP, is an endogenous peptide hormone produced by the heart and released into the bloodstream in response to increased blood volume and pressure. The body also releases ANP during panic attacks, which led researchers to ask whether administering ANP could suppress a panic episode in progress.

Two small double-blind, placebo-controlled crossover trials investigated exactly that. Both enrolled patients with panic disorder diagnoses and used CCK-4, a naturally occurring panicogenic compound, to induce experimental panic attacks under controlled conditions. In one study, panic attacks occurred in two out of ten patients who received ANP intravenously, compared to seven out of ten in the placebo group. The reduction was both statistically meaningful and clinically striking for such a small sample. The mechanism involves ANP inhibiting the HPA axis, the hypothalamic-pituitary-adrenal stress-response cascade, while suppressing corticotropin-releasing hormone circuits that drive anxiety responses and producing sympatholytic effects, meaning it damps down overactivity in the sympathetic nervous system.

The critical limitation is that all of this evidence comes from experimentally induced panic attacks in a laboratory setting, not from spontaneous panic attacks in real-world patients. No follow-up trials have been conducted, and ANP is not a commercially available therapeutic product. It is an endogenous hormone rather than a compound that exists as a research chemical for self-administration. Its position in this list reflects that it carries the most rigorous panic-specific clinical data of any compound here, while also being the least accessible as a practical option. It belongs in this guide because it is central to the scientific conversation about panic and peptides, and because understanding the ANP pathway illuminates why several other compounds on this list work the way they do.

4. Neuropeptide Y: The Brain's Endogenous Fear Brake

Neuropeptide Y, or NPY, is one of the most abundant peptides in the mammalian brain and plays a central role in regulating the stress response. Researchers have described it as the brain's natural brake system for anxiety and fear. During highly stressful experiences, endogenous NPY appears to limit how intensely the fear response escalates, which is why investigators began looking at it as a potential intervention for anxiety disorders, particularly those with a trauma component.

VA-funded research published in 2014 found that intranasal administration of NPY in rodent models significantly reduced both anxiety behavior and exaggerated startle responses, two of the core features seen in PTSD and panic-adjacent fear states. The mechanism involves NPY acting on receptors throughout the amygdala and hypothalamus to dampen the output of the fear network, essentially turning down the volume on the alarm signal rather than blocking it downstream.

Human trial data for NPY in anxiety disorders is limited. It remains a research compound with no approved therapeutic use and no established self-administration protocol. The evidence here is almost entirely preclinical, and the translation from animal models to human panic disorder has not been established. What makes NPY relevant to this list is the mechanistic logic: it acts on the same fear-regulation circuitry implicated in panic disorder, and the researchers studying it are directly motivated by conditions like PTSD and panic disorder. For anyone mapping the broader landscape of peptides and panic, NPY represents one of the most scientifically grounded research targets in the pipeline, even if it is not practically accessible as a therapeutic option today.

5. DSIP: For the Sleep and Stress-Hormone Substrate of Panic

Delta Sleep-Inducing Peptide, known as DSIP, is an endogenous neuropeptide involved in regulating sleep architecture, specifically the slow-wave sleep phases that are most restorative. It works partly through glucocorticoid receptor pathways to normalize HPA axis activity, the hormonal stress-response system that tends to be chronically dysregulated in people with panic disorder.

The connection to panic attacks is indirect but mechanistically coherent. Sleep disruption and HPA axis dysregulation are two of the most consistently observed biological features of panic disorder. Cortisol is elevated, stress hormones cycle abnormally, and sleep quality suffers, and each of those factors independently increases biological vulnerability to panic episodes. DSIP addresses that underlying substrate rather than acute panic symptoms. It does not modulate GABA receptors or act on fear circuits the way Selank does. Its value proposition is restorative: improving the quality of deep sleep and normalizing the stress hormone environment that panic attacks grow out of.

The evidence base for DSIP in any human condition is thin. No clinical trial has studied it specifically in panic disorder patients. What exists is a combination of research on its sleep and cortisol effects, mostly from smaller studies, and community-reported use from people managing anxiety and stress as part of a broader peptide approach. For panic-specific applications, the evidence here is experiential rather than clinical. DSIP appears in this guide because it is a genuine part of the conversation in peptide communities focused on anxiety and panic, and its indirect mechanism offers something the other compounds on this list do not: a focus on the hormonal and sleep substrate rather than the acute fear response itself.

6. Oxytocin: For the Social Threat Component of Panic

Oxytocin is a neuropeptide hormone produced in the hypothalamus and widely known for its roles in social bonding, trust, and childbirth. It is FDA-approved for obstetric use, making it the only compound on this list with any formal regulatory approval, though that approval has nothing to do with anxiety or panic. Its use for anxiety-related goals is entirely off-label and experimental.

The mechanism relevant to panic involves how oxytocin modulates the amygdala's threat-processing activity. The amygdala is the brain region most directly involved in generating fear responses, and oxytocin receptors are densely distributed there. Research suggests that oxytocin reduces the amygdala's reactivity to social threat cues and moderates the fear generalization that underlies many anxiety disorders. For panic disorder specifically, the relevance is strongest when episodes have a social anxiety component, meaning they are more likely in social situations or when fear of social judgment amplifies an attack.

The human evidence for oxytocin in panic disorder is limited. Studies in social anxiety and stress-related conditions point toward real anxiolytic effects on amygdala reactivity, but panic-disorder-specific trials are scarce. Community use for anxiety is real, particularly in functional medicine and biohacking contexts where nasal spray oxytocin is part of broader stress and anxiety protocols. No human clinical trial data has been published specifically on oxytocin for panic attacks as of 2026. Its position here reflects genuine ongoing use and discussion in the anxiety-peptide community, with the honest caveat that panic-specific evidence is essentially absent.

7. PE-22-28: An Emerging Research Option for Anxiety and Panic

PE-22-28 is a synthetic analog of spadin, itself a fragment of a naturally occurring protein involved in regulating TREK-1 channels in the brain. TREK-1 is a potassium channel expressed in regions tied to mood regulation and stress responses, and blocking it appears to promote rapid neurogenesis, the growth of new neurons, in areas like the hippocampus.

The interest in PE-22-28 for anxiety and panic states comes from its antidepressant and anxiolytic mechanism. Panic disorder has significant neurobiological overlap with depression, and compounds that promote neuroplasticity and rapid mood stabilization are being explored across both conditions. PE-22-28 has drawn attention in competitive analyses of anxiety peptides because its mechanism differs from both the GABAergic route of Selank and the neurotrophin route of Semax, offering a third pathway toward mood and anxiety regulation.

The evidence is limited. Most of what exists involves rodent models of depression and anxiety, and no panic-disorder-specific human trial data has been published as of 2026. Community use is present but less developed than for Selank, Semax, or DSIP. This is the least evidence-supported compound in the list, and its inclusion reflects that it appears in community discussions among people actively exploring peptide options for anxiety and panic rather than any clinical data pointing specifically at panic attacks. For someone already familiar with this field who is looking at the research frontier, PE-22-28 is worth knowing about. For someone beginning to explore options, it would not be the logical first consideration.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for panic attacks?

No peptide is currently FDA-approved specifically for treating panic attacks or panic disorder. The compounds in this guide are either approved for unrelated indications in the United States, approved for anxiety or other conditions in countries like Russia, or classified as research chemicals with no approved therapeutic use anywhere. Standard FDA-approved treatments for panic disorder remain SSRIs, SNRIs, and short-term benzodiazepines under physician supervision.

Is BPC-157 safe for people with panic disorder?

Based on a consistent pattern of community reports, BPC-157 appears to carry a meaningful risk of triggering panic attacks in people who are already prone to them. Multiple users have reported severe episodes beginning within the first days of starting BPC-157, sometimes requiring emergency contact. BPC-157 is not included as a treatment option in this guide, and people with a history of panic disorder should discuss this safety signal with a clinician before considering it.

How does Selank differ from benzodiazepines for anxiety?

Selank and benzodiazepines both act on GABA-A receptor pathways, but they appear to do so through different mechanisms. Clinical comparison studies found Selank produced anxiety reduction comparable to diazepam while avoiding the sedation and dependence risks associated with benzodiazepines. User reports are consistent with this profile: people describe Selank as calming without impairing focus or creating the tolerance and withdrawal dynamics that make long-term benzodiazepine use problematic. That said, Selank is not FDA-approved, its sourcing is unregulated in the United States, and it has not been tested in large-scale trials.

How long before these peptides show effects on anxiety?

The timeline varies considerably by compound and by individual. Selank users in community protocols frequently report noticing effects within the first few days of use. Compounds that work through slower neuroplasticity mechanisms, such as Semax via BDNF upregulation or DSIP via HPA axis normalization, would logically take longer to produce meaningful change, likely weeks rather than days. No standardized clinical timeline exists for any of these compounds in panic disorder because panic-specific trials are either very limited or entirely absent.

Do these peptides require a prescription?

In the United States, most of the research-chemical compounds in this guide do not require a prescription to obtain because they are not approved drugs and are sold through research chemical vendors. Oxytocin is the exception, as it is an FDA-approved pharmaceutical and does require a prescription for pharmaceutical-grade access. Compounding pharmacy access for several of these compounds has tightened since 2023 regulatory changes. Working with a physician or telemedicine clinic knowledgeable about peptide therapies is strongly advisable before pursuing any of them.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and user-reported real-world use of peptides for panic attacks in one place.